Is Your Wegovy Wearing Off by Thursday? Probably Not.

You take your shot on Sunday. By Thursday, the fridge starts talking to you again — that low hum of hunger you'd half forgotten was ever a thing. And the worry lands right behind it: is it wearing off already? Should I just take the next one a day early?

Here's the short version, before the why. Almost certainly, it hasn't worn off. Semaglutide — the molecule inside Wegovy for weight and Ozempic for type 2 diabetes — sticks around in your body a lot longer than seven days. What you feel on Thursday can be real, but it isn't the medicine draining out of you between shots. And the answer is not an early dose, a bonus dose, or a quiet bump in strength on your own.

One quick boundary so we don't wander. This piece is about the weekly cycle — the "it feels weaker by the weekend" question. It is not about a month-scale stall, where the scale stops moving for weeks on end. That's a different animal, and it lives over in the plateau guide. Keep the two apart and everything here gets simpler.

First, the reassuring part: the drug doesn't drain out between shots

The single fact that dissolves most of this worry is the half-life.

Semaglutide has an elimination half-life of about 1 week. Plainly: it leaves your system slowly, taking roughly seven days for the level in your blood to fall by half. It clears so gradually that it's still in your circulation for about 5 to 7 weeks after your last shot. So the idea of it "running out" a few days into a weekly cycle doesn't match how the molecule behaves. On day five, day six, day seven, there's still plenty of drug on board.

Once-weekly dosing is designed to sit on top of that slow clearance. Because each shot lands while the previous one is still very much present, the levels stack into a steady background instead of a spike-and-crash. On Wegovy at 2.4 mg once weekly, the average steady-state concentration runs around 75 nmol/L — a plateau your body holds between doses, not a peak that collapses by midweek.

And that background level is doing something specific. GLP-1 is a physiological regulator of appetite and caloric intake — appetite is the lever the whole drug pulls. So when the talk turns to hunger coming and going, we're standing right on the system the medicine works through. That's exactly why a small shift gets noticed so sharply: you're monitoring the one dial the drug moves.

The weekly rhythm isn't a guess, either. In STEP 1 (the 2021 NEJM trial that put this dose on the map), people took once-weekly semaglutide at 2.4 mg for 68 weeks. The schedule held up across all of that — the weekly cadence is the tested one, not something that quietly falls apart between injections.

The half-life is the whole story here. About a week to clear by half, 5 to 7 weeks to leave entirely — so between two weekly shots, the drug never actually empties out. You're on a plateau, not a cliff.

Why the back half of the week can feel a little hungrier

Now the honest part, because pretending Thursday feels identical to Monday would be its own kind of lie.

There's a real quirk in the pharmacology. The half-life (about a week) is close to the dosing interval (a week), so the level does drift down a bit in the day or two before your next shot — a shallow trough at the bottom of the plateau. It's not a cliff, and it's nowhere near "empty." But it isn't perfectly flat either. For some people, that gentle dip is enough to notice a touch more appetite late in the week. That experience is allowed to be real.

Here's the part I'd gently push back on, though: the drug is rarely the only variable moving. Hunger answers to a lot of masters — a short night's sleep, a stressful stretch, meals that skew light on protein, the plain pull of habit and boredom. Any of those can nudge appetite up on a Thursday, and it's easy to pin the whole thing on "the shot is fading" when the shot may be the smallest piece.

I'm not going to hand you a "you'll feel it on day X" number, because there isn't an honest one — the size of the dip varies person to person, and inventing precision would be worse than admitting the spread. Some people never notice a thing. Some feel a mild late-week creep. Both are ordinary.

Late-week hunger can be two things at once: a shallow, real dip in drug level, plus everything else in your week — sleep, stress, protein, habit. Don't assume the medicine is the only thing that moved.

This is not the same thing as the drug "wearing off"

The language people reach for — "it stopped working," "I've built up a tolerance," "my Ozempic quit on me" — sounds intuitive and mostly isn't accurate across a single week.

Remember where we started: at steady state, the drug is still present at that ~75 nmol/L background, holding its level between shots. A little more appetite on Thursday isn't evidence that the medicine has gone inert, or that your body has learned to shrug it off. The pharmacology hasn't changed between Sunday and Thursday; the amount in your system has barely moved.

Real, months-long flattening — where progress stops no matter what you do — is a genuine topic, but it's a separate one, and you don't diagnose it from a single hungry evening. If that's what you're seeing, the right home for it is the plateau guide, not a snap verdict that the drug "failed." Treating one late-week evening as proof of failure is how people talk themselves into the exact move they shouldn't make — which is the next section.

The one move to avoid: don't reach for an early or extra shot

This is the part I'd underline twice if I could. Whatever you do with a hungry Thursday, don't fix it by touching your own dose or schedule.

Three specific things stay off the table on your own initiative:

• Taking your next shot early — pulling Sunday's dose forward to Friday because you feel it fading.
• Adding an extra shot mid-week — a "top-up" on top of your weekly dose.
• Nudging your dose up yourself — reaching for more milligrams because the level feels light.

The reason is plain. More semaglutide, sooner, stacks on top of a level that's still substantial. Overshooting the dose is how you land the harsher side of this drug — heavy nausea, vomiting, and the dehydration that rides along with them. And if you also take medication for diabetes, pushing the GLP-1 dose can tip you toward low blood sugar. Dose and timing aren't knobs to freelance; they're clinical decisions that belong with the person who prescribed the drug.

If you want the full logic of when and how the shot is taken — day, time, what happens if you're late — that's its own walkthrough in the weekly-shot timing guide. The one-line version: keep the day you picked, and don't rearrange the schedule to chase a craving.

When the hunger is telling you something real

None of this means you grit your teeth and ignore your body. It means you route the signal to the right place.

If the hunger isn't a one-off Thursday but a steady, week-after-week return — or your weight loss has genuinely stalled — that pattern can be a legitimate sign that you're ready for the next rung on the dose ladder. GLP-1 doses are meant to step up over time; a starting dose is a starting dose. But moving up a step is titration, and titration is a clinical call your prescriber makes with your chart in front of them — not something you approximate at home. Bring them the pattern: "the appetite control fades reliably by midweek, every week." That's clean, specific information, and it's exactly what guides a dose conversation. How that ladder usually goes is laid out in the dose-escalation guide.

While you wait for that visit, the ordinary levers are worth pulling, and they're just plain healthy habits, not medical instructions. Enough protein tends to blunt hunger more than most things — there are real numbers in the protein guide. Regular meals beat a skipped-lunch-then-ravenous-evening pattern. Decent sleep quiets appetite; a run of short nights amplifies it. None of these replace the dose your doctor sets, but they're the difference between a manageable Thursday and a rough one.

A reliable, every-week fade in appetite isn't a reason to self-dose — it's a reason to book a check-in. "It stops holding by midweek" is a clean signal your prescriber can act on. Your job is to report it, not to prescribe around it.

Where the doctor draws the safety lines

Timing and hunger are the low-stakes end of this. The next part isn't — and it's worth keeping three levels of seriousness separate instead of collapsing them into one anxious paragraph.

At the top is a hard stop. On the US label, semaglutide (Wegovy) carries the FDA's most serious warning tier around thyroid C-cell tumors, and it's a flat contraindication for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). That isn't a weigh-the-tradeoffs situation — that history rules the drug out.

One level down is a warning, not a ban. Acute pancreatitis has been reported with these medicines. The label doesn't block treatment over it up front; it tells the prescriber to stop the drug if pancreatitis is suspected. In plain terms: severe, persistent belly pain is a same-day phone call, not something to push through.

Then the everyday tier — nausea, vomiting, diarrhea, and constipation, the gut reactions most people associate with GLP-1s. These aren't rare, and they aren't a reason to quit; they're the familiar background of getting started, and a big part of why doses ramp slowly instead of all at once.

One caveat on all of that: "boxed warning," "contraindication," and the exact wording are US FDA language. If you're reading from another country, your own regulator's approvals and phrasing can differ — the tiers of seriousness carry over, but check the specifics against your local label. Same goes for the cousins: tirzepatide (Zepbound for weight, Mounjaro for diabetes) is also a once-weekly shot, but it's a different molecule — a dual GIP/GLP-1 agonist — with its own pharmacokinetics, so don't copy Wegovy's exact numbers onto it.

One rule worth taping to the fridge

Strip this whole piece down to a single line and it's this: you never freelance the dose or the schedule.

A little more hunger by Thursday is, most of the time, a shallow trough plus an ordinary human week — not the drug quitting, and not a reason to move a shot up, add one, or climb the dose on your own. The medicine is still there, holding its steady level, doing the quiet work it does. If the fade is real and repeats every week, that's information for your next appointment, where a dose step gets decided properly. If you're near the maintenance stage and wondering how any of this shifts once you stop climbing, that's its own path in the maintenance guide.

Everything here comes from published trials and the approved label, not from testimonials — and none of it can see your chart the way your own clinician can. So the Thursday hunger goes in your notes, not into an early injection. That one conversation is the only place a dose change should ever happen.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app